Amyris to Acquire Sweet-Protein Developer Oobli

The planned deal would pair Amyris’s fermentation manufacturing and strain engineering with Oobli’s sweet-protein ingredient platform, with closing expected in the coming weeks.

Amyris, Inc., an Emeryville, California-based vertically integrated biomanufacturing company, has announced plans to acquire Oobli Inc., a Davis, California-based developer of fermentation-derived sweet proteins. The acquisition is expected to close in the coming weeks.

Amyris said the transaction would combine its scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. It follows Amyris’s expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris described the acquisition as a strategic commercial and technology expansion intended to accelerate its presence in protein- and peptide-based solutions across end markets.

A fermentation-based sweet-protein platform

Oobli has spent the past decade refining a fermentation process for producing sweet proteins naturally found in rare fruits and berries near the equator. Its commercial portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli describes these ingredients as the first of their kind in the sugar-reduction category.

According to the announcement, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says they deliver sweetness without gut disruption or blood sugar spikes. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor, according to the company.

Oobli is targeting food and beverage categories including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery. The company points to growing consumer awareness of metabolic health and the benefits of sugar reduction as factors supporting demand for new sweetness solutions. Amyris said Oobli’s commercial portfolio of sweet proteins would be the first to benefit from the combined platform.

Executive views on scale and reach

Amyris CEO Kathy Fortmann said Oobli’s commercial and technology platform complements Amyris’s own. She said Amyris aims to bring its commercial scale and resources to accelerate what she called the “sweet revolution.” Fortmann also said that combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the combined company’s capabilities in food and beverage, personal care, flavor and fragrance, agriculture and beyond.

Oobli CEO Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions. Fortmann added that biomanufactured solutions tend to succeed when they align with consumer demand and market needs, and said Oobli’s platform is intended to address sweet taste, sugar reduction and clean label simultaneously.

Commercial continuity

Amyris said existing customer commitments and brand partnerships would continue to be honored without interruption as Oobli’s sweet-protein portfolio expands within the larger company. The companies expect the transaction to close in the coming weeks.

IN

Imani Ndlovu

Imani Ndlovu covers industrial water treatment chemicals, including coagulants, flocculants, scale inhibitors, and corrosion inhibitors for plant and process audiences. Coverage compares jar test results, coagulant and flocculant dosing ranges, pH, turbidity, sludge volume, and scale or corrosion indicators under stated water conditions. The work helps plant managers, process engineers, and industrial buyers evaluate treatment options, interpret supplier data, and make sourcing or operational decisions without treating a bench result as a full-scale performance guarantee.